No Data
No Data
Express News | Kymera Therapeutics Inc : B. Riley Raises Target Price to $36 From $31
Stocks to Watch: Kymera Therapeutics, NexGel, Helios Technologies
By Sabela Ojea Kymera Therapeutics on Monday said Sanofi intends to expand its ongoing Hidradenitis Suppurativa and Atopic Dermatitis Phase 2 trials. Shares of the clinical stage biopharmaceutical com
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours
Kymera Therapeutics (KYMR) said Monday Sanofi (SNY) has informed the company over its plan to expand the ongoing Hidradenitis Suppurativa and Atopic Dermatitis mid-stage trials to more rapidly progres
Kymera Therapeutics Advances With Sanofi in Phase 2 Trials
Kymera Intends To Expand Hidradenitis Suppurativa And Atopic Dermatitis Phase 2 Trials To More Rapidy Progress Towards Pivotal Studies Following Interim Review Of Safety And Efficacy
Kymera Intends To Expand Hidradenitis Suppurativa And Atopic Dermatitis Phase 2 Trials To More Rapidy Progress Towards Pivotal Studies Following Interim Review Of Safety And Efficacy
Express News | Kymera Announces Expansion of KT-474 (SAR444656) Hs and Ad Phase 2 Studies Following Interim Review of Safety and Efficacy